Healthcare Private Placement and M&A Transactions Review Week Ending February 26 2023

Capsida Biotherapeutics: The company raised $70 million of venture funding from AbbVie on February 23, 2023. The company is a developer of targeted gene therapies intended to treat debilitating and life-threatening genetic disorders in both the central nervous system and non-CNS indications.

Transcend Therapeutics: The company raised $40 million of Series A venture funding in a deal led by Alpha Wave Global and Integrated on February 23, 2023. Global Founders Capital, Emerald Development Managers, and other undisclosed investors also participated in the round. The company is a developer of psychoactive compounds intended for neuropsychiatry focused on patient access.

Xeltis: The company raised EUR 32 million of Series D2 venture funding from China Grand Pharmaceutical and Healthcare Holdings, DaVita Venture Group and EQT Life Sciences on February 22, 2023. The company is a developer of medical devices designed to provide a restorative approach to cardiovascular therapy.

Bivacor: The company raised $15 million of venture funding from undisclosed investors on February 21, 2023. The company is a developer of an artificial heart-pumping device designed to take over the complete function of a patient’s failing heart.

Current Surgical: The company raised $3.2 million of venture funding in a deal led by SciFounders, True Ventures and 1517 Fund on February 21, 2023. The company is a developer of a smart surgical needle designed for minimally invasive tumor detection and ablation.

Trince: The company raised EUR 2 million of Series A venture funding from undisclosed investors on February 21, 2023, putting the company’s pre-money valuation at EUR 4.75 million. The company is a developer of transfection technology intended to facilitate the delivery of molecules into cells, both in vitro and ex vivo.

Curia.ai / Aledade: The company, a subsidiary of Foundry.ai, was acquired by Aledade for an undisclosed amount on February 21, 2023. The company is a developer of a cloud-based software platform designed to deliver measurable business and clinical value.

Enliven Therapeutics / Imara: The company acquired Imara through a reverse merger, resulting in the combined entity trading on the Nasdaq stock exchange under the ticker symbol ELVN on February 23, 2023. The company is a developer of small molecule kinase inhibitors designed to treat cancer patients.

Infinity Pharmaceuticals / MEI Pharma: The company reached a definitive agreement to be acquired by MEI Pharma for an undisclosed amount on February 23, 2023. Infinity Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel medicines for the treatment of specific cancers.

Jounce Therapeutics / Redx Pharma: The company reached a definitive agreement to be acquired by Redx Pharma for an undisclosed amount on February 23, 2023. Jounce Therapeutics Inc is a clinical stage immunotherapy company.

Razor Genomics / Dragon Scientific: The company, a subsidiary of OncoCyte, was acquired by Dragon Scientific for an undisclosed amount on February 22, 2023. The company is a developer of a genomic mutation detection technology designed to identify cancer and other disease-causing mutations from patient biopsy samples.

Tmunity / Kite Pharma: The company was acquired by Kite Pharma, a subsidiary of Gilead Sciences, for an undisclosed amount on February 22, 2023. The company is a developer of a biotherapeutics platform designed to deliver cell immunotherapy to patients with devastating diseases.